Barclays initiated coverage on OptimizeRx with a new price target
$OPRX
Business Services
Consumer Discretionary
Barclays initiated coverage of OptimizeRx with a rating of Equal Weight and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $7.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 12/20/2024 | $5.50 | Equal-Weight | Stephens |
| 7/25/2024 | $18.50 | Buy | B. Riley Securities |
| 4/4/2024 | $15.00 | Mkt Outperform | JMP Securities |
| 1/3/2024 | $15.00 | Equal Weight | Barclays |
| 2/2/2023 | $30.00 | Buy | B. Riley Securities |
| 11/1/2022 | $19.00 | Buy | Stifel |
| 7/15/2022 | $38.00 | Outperform | SVB Leerink |
RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously
Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50
B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50
WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025Stifel 2025 Boston Cross Sector 1x1 Conference, Boston, June 3 – 4, 202545th Annual William Blair Growth Stock Conference, Chicago, June 3 – 5, 2025The Citizens Medical Devices and Healthcare Services Forum, Boston, June 17, 2025 B. Riley Securities 25th Annual Invest
Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025
WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate citizen. "Our stakeholders continue to expect us to transparently disclose our commitment to environmental, social, and governance responsibilities," stated Marion
10-Q - OptimizeRx Corp (0001448431) (Filer)
8-K - OptimizeRx Corp (0001448431) (Filer)
SCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)
WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the "Board"), it intends to appoint a new independent director to its Board of Directors during the second half of this year. With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema w
WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition. "The time is right to pass the reins on to an incredible team, ready to carry the legacy forwa
Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, May 12, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free
Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024. For the Year EndedDecember 31,Key Performance Indicators (KPIs)* 2024 2023 (in thousands, except percentages)Average revenue per top 20 pharma
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
SC 13G - OptimizeRx Corp (0001448431) (Subject)
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)